The Role of Angiopoietins as Potential Therapeutic Targets in Renal Cell Carcinoma
作者: Xiaoen WangAndrea J. BullockLiang ZhangLin WeiDongyin YuKedar MahagaokarDavid C. AlsopJames W. MierMichael B. AtkinsAngela CoxonJon OlinerRupal S. Bhatt
作者单位: 1Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
2Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
3Oncology Research, Amgen Inc, Thousand Oaks, CA
4Departments of Oncology and Medicine, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC
刊名: Translational Oncology, 2014, Vol.7 (2), pp.188-195
来源数据库: Elsevier Journal
DOI: 10.1016/j.tranon.2014.02.003
原始语种摘要: Abstract(#br)Angiopoietin 2 (Ang2) is a secreted glycoprotein upregulated at sites of angiogenesis and has been implicated in cancer neovascularization. Recent studies have suggested efficacy of combined Ang and vascular endothelial growth factor receptor (VEGFR) inhibition for patients with metastatic renal cell carcinoma (mRCC). We measured Ang2 expression in human tissue and plasma, and tested the effect of dual Ang1/2 (trebananib; AMG386) or Ang2 alone (L1-7) inhibition with VEGFR inhibition on murine RCC growth and blood flow. Ang2 levels were higher in human tumors than normal tissues with RCC ranking highest for Ang2 expression across all tumor types tested. Plasma Ang2 was significantly higher in patients with mRCC compared to controls or patients with stage I disease. Plasma Ang2...
全文获取路径: Elsevier  (合作)
影响因子:3.393 (2011)

  • 新陈代谢的 鼠灰色
  • inhibition 抑制
  • combined 组合
  • carcinoma 癌症
  • activity 活度
  • RCC Readiness Condition Coder
  • invasive 侵入的
  • murine 鼠灰色
  • metastatic 鼠灰色
  • angiogenesis 血管生成
  • efficacy 效验